featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies

Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the treatment of wet age-related macular degeneration (AMD).  According to the company, the product is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept “and the ability […]

Read full story
Featured

Phase II study results on intravitreal (IVT) pegcetacoplan (a synthetic cyclic peptide) for the treatment of geographic atrophy (GA) secondary to ARMD

A Phase II study investigating intravitreal pegcetacoplan for the treatment of geographic atrophy (GA), secondary to age-related macular degeneration (AMD), has announced the reporting of statistically significant reductions in the growth of GA, compared with sham treatment.  Results, published in the journal Ophthalmology (article in press, 2019), showed the GA growth rate was reduced by […]

Read full story
Research

Research on research: systematic reviews for retinal and vitreous conditions are classified as not reliable

Researchers at the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, have reported that systematic reviews for retinal and vitreous conditions were deemed to be “as not reliable”.  Just under 60% of systematic reviews were judged to be inadequate and a primary concern indicates that there is a lack of a comprehensive […]

Read full story
Introduction

October 18th, 2019: “EURETINA-Brief”© Issue No. 200

by Dr. Gearóid Tuohy     Dear EURETINA Members,   A very warm welcome to the October 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource […]

Read full story
Research

Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data

Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides a real-world setting, albeit different to the outcome data reported from clinical trial publications. In follow-up to real-world 5-year outcome data on a retrospective population, the results indicate that a […]

Read full story
Introduction

April 16th, 2019: “EURETINA-Brief” Issue No. 190

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

Latest News

Book Review